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Fibroblast growth factor (FGF)2 is a ubiquitously ex-
pressed pleiotropic growth factor with many recognised 
cellular targets and tissue eﬀ   ects. Its role in articular 
chondrocytes and mesenchymal cells has been exten-
sively studied, but published data are plagued by apparent 
contradiction and inconsistency. Th  e paper by Yan and 
colleagues reported in the previous issue of Arthritis 
Research & Th  erapy proposes a novel and elegant expla-
na  tion for these seemingly disparate and conﬂ  icting ﬁ  nd-
ings [1]. FGFs signal through one of four FGF receptors 
(FGFRs), and the authors show that the catabolic eﬀ  ects 
of FGF2 (induction of proteases such as matrix metallo-
proteinase 13 (MMP13) and ADAMTS5 (a disintegrin 
and metalloproteinase with thrombospondin motifs 5)), 
as well as suppression of matrix synthesis, are speciﬁ  cally 
mediated through FGFR1 ligation. Th  ey propose that 
FGF2 signalling via FGFR3, the other major cell surface 
receptor on chondrocytes, leads to a dominant anabolic 
drive. Th   is is supported by the ﬁ  nding that FGF18, which 
is unusual because it is less promiscuous than FGF2 and 
selectively activates only FGFR3 [2], is able to stimulate 
proteoglycan synthesis. Other reports have conﬁ  rmed 
the anabolic nature of FGF18 and an ongoing clinical trial 
of intraarticular injection of recombinant FGF18 in 
osteoarthritis is currently being conducted by Merck 
Serono (reviewed in [3]).
Our own studies have demonstrated that FGF2 is 
stored within the pericellular matrix of chondrocytes 
attached to the heparan sulphate chains of perlecan [4]. 
Th  is pool of growth factor is liberated upon injury or 
mechanical compression of the matrix [5]. We demon-
strated that, at least in young mice, the overall eﬀ  ect of 
FGF2 in the joint is benign. Indeed, mice lacking FGF2 
(FGF2 null mice) developed accelerated osteo  arthritis 
(with age and following surgical joint destabilisation), 
and this could be reversed by delivery of subcutaneous 
recombinant FGF2 [6]. When gene expression analysis 
was performed in FGF2 null joints after induction of 
osteoarthritis, there was a super-induction of ADAMTS5
mRNA, suggesting that FGF2 normally suppresses 
ADAMTS5. Th   is was consistent with the ability of FGF2 
to suppress interleukin-1-driven aggrecanase activity in 
normal human articular cartilage explants [7]. Th  ese 
persuasive anti-catabolic activities of FGF2 could well be 
dependent upon diﬀ  erences in the balance of FGFRs in 
these tissues, although it is also worth noting that in vivo
many other cells within the joint respond to FGF2 
(besides chondrocytes) and these could be contributing 
to the increased disease seen in FGF2 null mice. All the 
same, these studies alert us to the possibility that receptor 
expression diﬀ  ers between diﬀ  erent tissues, ages of tissue 
and possibly even species.
Th   e authors also make the interesting observation that 
the FGFR balance is dynamic. FGF2 itself is able to 
suppress the expression of FGFR3, whilst bone morpho-
genetic protein (BMP7) is able to augment expression. 
Th  is does raise the question as to whether receptor 
expression is signiﬁ   cantly altered when cartilage is 
explanted and cells are isolated. As FGF2 itself is released 
upon explantation of cartilage [5], this process may aﬀ  ect 
Abstract
Fibroblast growth factor 2 (FGF2) is a highly abundant 
growth factor found within the pericellular matrix of 
articular chondrocytes, but studies investigating its role 
have been confl  icting. The paper reported by Yan and 
colleagues in the previous issue of Arthritis Research & 
Therapy proposes that diff  erences in responses to FGF2 
are most likely due to changes in the balance between 
the two major articular cartilage FGF receptors, 
FGFR1 and FGFR3. They show that the catabolic and 
anti-anabolic eff  ects of FGF2 are mediated primarily 
through FGFR1 whereas the benefi  cial eff  ects are 
through FGFR3. This balance is dynamic and is altered 
in disease and following growth factor stimulation in 
vitro.
© 2010 BioMed Central Ltd
Fibroblast growth factor 2: good or bad guy in the 
joint?
Tonia L Vincent*
See related research by Yan et al., http://arthritis-research.com/content/13/4/R130
EDITORIAL
*Correspondence: tonia.vincent@kennedy.ox.ac.uk
Kennedy Institute of Rheumatology, University of Oxford, 65 Aspenlea Road, 
London, W6 8LH, UK
Vincent Arthritis Research & Therapy 2011, 13:127 
http://arthritis-research.com/content/13/5/127
© 2011 BioMed Central Ltdthe balance of FGFRs in the resulting assay material, 
perhaps leading to skewing of the natural balance of 
receptors and tending towards a more catabolic pheno-
type in cultured cells/explants in vitro. It is not known 
whether FGF18 and BMP7 are also endogenous peri-
cellular matrix-bound proteins, and whether they too are 
liberated in response to injury. FGF18 has been shown to 
bind the core protein of perlecan in vitro [8] and it is able 
to form FGFR3-activating complexes with chondrocyte-
derived perlecan [9]. BMP7 is made by chondrocytes and 
is known to bind to heparan sulphates and ﬁ  brillin, and 
thus may also be bound within the pericellular matrix 
[10]. Th  e controlled release of these factors within the 
immediate vicinity of the cell surface could, like FGF2, 
represent a rapid and eﬃ   cient way of controlling chon-
dro cyte  responses.
Th  e question of whether the FGFR balance changes 
with age and with disease is an interesting and important 
one. Yan and colleagues show that there is a signiﬁ  cant 
decrease in FGFR3 expression in human osteoarthritis 
cartilage compared to tissue from normal post mortem 
samples, which suggests that release of pericellular FGF2 
in diseased cartilage may lead to predominantly catabolic 
eﬀ   ects and the beneﬁ   ts of exogenous FGF18 will no 
longer be realisable. Th  e extent to which this will limit 
the utility of FGF18 treatment in human disease will be 
disclosed in due course when the Merck Serono trial has 
been completed. In the meanwhile, an important focus 
will be to develop strategies that augment FGFR3 levels 
within diseased tissues in order to potentiate the bene-
ﬁ  cial eﬀ  ects of all FGF family members.
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